1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Mankind Pharma Limited

Mankind Pharma Limited

MANKIND.NS
Mankind Pharma LimitedIN flagNational Stock Exchange of India
2,525.10
INR
-6.90
- -
1.04TMarket Cap
Mankind Pharma Limited
MANKIND.NS
(National Stock Exchange of India)

Recent

price

2,525.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
2026
TTM
FRC
146.42
155.13
194.25
218.41
256.11
302.19
345.92
317.15
Revenue per Share
25.72
31.59
35.78
32
47.75
49.28
46.35
46.5
Basic EPS, GAAP
21.01
20.59
-35.59
24.49
44.02
46.6
57.76
- -
Free Cash Flow per Basic Share
9.09
- -
- -
- -
- -
- -
1
- -
Dividend per Share
102.49
133.39
169.13
201.01
248.61
295.78
335.45
- -
Book Value per Share
90.5
120.41
110.38
145.91
197.03
-50.7
10.35
- -
Tangible Book Value per Share
401
401
401
401
401
404
413
407
Basic Weighted Avg Shares
58,652
62,144
77,816
87,494
102,593
122,074
142,776
129,099
Sales/Revenue/Turnover
25.1
25.9
24.21
18.76
21.83
20.61
19.86
19.02
Operating Margin (%)
991
1,190
1,666
3,259
3,982
6,212
8,862
7,372
Depreciation Expense
10,304
12,654
14,335
12,819
19,129
19,910
19,129
18,928
Net Income, GAAP
26.54
23.56
26.42
21.63
19.06
20.26
16.92
20.15
Effective Tax Rate (%)
17.57
20.36
18.42
14.65
18.65
16.31
13.4
14.66
Profit Margin (%)
15,636
25,532
17,834
24,647
44,485
13,247
4,470
- -
Working Capital
532
622
522
283
326
55,402
28,927
- -
LT Debt
36,716
48,629
63,163
76,233
95,758
145,682
165,610
- -
Total Equity
- -
27.42
22.53
17.14
20.62
12.23
10.27
- -
Return on Invested Capital (%)
- -
24.69
21.5
15.85
20.29
14.84
11.74
372.04
Return on Capital (%)
- -
26.78
23.66
17.29
21.24
18.18
14.83
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
29,712
- -
LT Borrowings
- -
55,262
- -
LT Finance Leases
- -
140
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
413
- -
Market Capitalization
1,155,694
979,720
944,313

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
69,883
- -
Cash, Cash Equivalents & STI
- -
22,343
- -
Accounts Receivable, Net
- -
15,383
- -
Inventories
- -
20,937
- -
Total Current Liabilities
- -
56,636
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
29,712
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
28.4%
13.68%
Free Cash Flow
- -
-65.71%
26.63%
Net Income, GAAP
- -
10.42%
-3.92%
Sales/Revenue/Turnover
- -
18.17%
16.96%
Total Cash Common Dividend
- -
- -
-88.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25,786
27,081
26,070
24,411
102,593
2025
28,678
30,614
31,988
30,794
122,074
2026
35,704
35,672
34,429
- -
142,776

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12.15
12.51
11.33
- -
47.75
2025
13.39
16.31
9.45
10.2
49.28
2026
10.62
9.9
13.44
- -
46.35

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
1
Similar Companies
Shineco, Inc. (TYHT)
Hua Medicine (Shanghai) Ltd. (HUMDF)
Biome Grow Inc. (BIO.CN)
Baijin Life Science Holdings Limited (1466.HK)
Ascend Wellness Holdings, Inc. (AAWH)
Cannibble Food-Tech Ltd. (PLCN.CN)
Business
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India with select international operations. The company offers a diversified portfolio exceeding 500 products across acute and chronic therapeutic areas including anti-infectives (15% domestic sales share), cardiovascular (15%), gastrointestinal (10%), respiratory (9%), anti-diabetic (9%), vitamins/minerals/nutrients (8%), gynaecology (8%), dermatology (5%), pain/analgesics (4%), and neuro/CNS (3%); prominent consumer healthcare brands encompass Manforce condoms, Prega News pregnancy detection kits, Unwanted-72 emergency contraceptives, Gas-O-Fast antacids, HealthOK multivitamins, and AcneStar anti-acne preparations. Founded in 1991 and commencing active operations in 1995, Mankind Pharma maintains headquarters in New Delhi, India, with 30 manufacturing facilities predominantly in Paonta Sahib (Himachal Pradesh), Haridwar (Uttarakhand), and Sikkim; it supports extensive domestic penetration via 16,000+ field force personnel, 13,000+ stockists, and coverage of over 500,000 doctors, deriving 92% of revenues from India across metros/Tier 1 (53%), Tier 2-6/rural (47%), and zones including North (35%), West (23%), South (23%), and East (19%), alongside exports to the US, Mexico, and pharmerging markets. Recent developments include the July 2024 announcement of a INR 13,630 crore acquisition of Bharat Serums and Vaccines (BSV) approved by CCI in October 2024, funded partly by a December 2024 INR 3,000 crore qualified institutional placement; a October 2025 INR 797 crore slump sale acquisition from BSV of its women's health Rx branded generics portfolio to bolster gynaecology offerings; in-licensing of AstraZeneca's Symbicort inhaler and Novartis' Inclisiran for respiratory and cardiac segments respectively during FY24; commissioning of India's first fully integrated dydrogesterone facility in Udaipur, Rajasthan; launch of ~150 SKUs with DMF-grade APIs and Nobeglar insulin glargine (Anti-Diabetic Launch of the Year); Phase 1 completion of NCE molecule GPR 119 for obesity/metabolic disorders; and incorporation of a wholly-owned subsidiary Mankind Pharma LLC in Russia in August 2025 for business expansion.